Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.

Biotechnology

Neurogene

Rachel McMinn

Jerry Lugo

Danielle Boyle

Tina Parikh

Kimberly Trant, RN, MBA

Ellery Mangas

Efsevia (Effie) Albanis

Craig Hebel

Bridget M.

Anandita Seth

Albena Patroneva

Andrew Mulberg

Christine Mikail

Ricardo Jimenez

Stuart Cobb

Arvind Sreedharan

The Scientific Team at Neurogene is responsible for researching and developing gene therapies targeting rare neurological disorders. This team leverages advanced AAV-based gene technology to deliver functional genes to patients with genetic deficiencies. Additionally, they focus on upstream process development, bioanalytical testing, molecular analytics, and ensuring quality control to advance the company’s pipeline of life-changing treatments.

Scientific Team

Leadership Team

Clinical Operations Team

Scientific Team

About

Team members

Other teams at Neurogene

Leadership Team

Clinical Operations Team